Arbutus Biopharma Corporation (ABUS) Covered Calls

Arbutus Biopharma Corporation is a clinical-stage biopharmaceutical company leveraging its expertise in virology to develop a functional cure for chronic hepatitis B virus (cHBV). The company’s pipeline includes imdusiran (AB-729), an RNA interference (RNAi) therapeutic, and AB-101, an oral PD-L1 inhibitor. Arbutus is also known for its proprietary lipid nanoparticle (LNP) delivery technology, which is the subject of significant ongoing intellectual property litigation in the vaccine sector.

You can sell covered calls on Arbutus Biopharma Corporation to lower risk and earn monthly income. Born To Sell's covered call screener gives you customized search capabilities across all possible covered calls but here are a couple of examples for ABUS (prices last updated Fri 4:16 PM ET):

Want to make money with covered calls?  Sign Up For A Free Trial

Arbutus Biopharma Corporation (ABUS) is dedicated to discovering and developing a combination of therapeutics to provide a finite, curative treatment for chronic hepatitis B. The company’s lead candidate, imdusiran (AB-729), is an RNAi agent designed to inhibit viral replication and reduce viral antigens, which often suppress the host’s immune response. In 2026, Arbutus reported significant progress in its Phase 2a clinical trials, demonstrating that nearly 46% of patients treated with imdusiran were able to discontinue nucleos(t)ide analogue (NA) therapy while maintaining viral suppression.

Beyond its internal pipeline, Arbutus holds a unique position in the biotech ecosystem due to its foundational Lipid Nanoparticle (LNP) delivery technology. In March 2026, the company reached a landmark $2.25 billion global settlement with Moderna related to the use of its LNP technology in COVID-19 vaccines. This settlement, alongside ongoing litigation with Pfizer and BioNTech, has significantly bolstered Arbutus’s balance sheet, extending its cash runway into 2028 and providing non-dilutive capital to fund the advanced clinical development of its HBV assets and its oral PD-L1 inhibitor, AB-101.

Competitive Landscape

The race for a functional cure for HBV is highly competitive, with ABUS contending against large pharmaceutical companies and specialized biotech firms. Competition is centered on the ability to achieve durable "functional cures"—defined as sustained loss of HBsAg—using finite treatment regimens.

1. Vir Biotechnology: A major rival with a similar RNAi and neutralizing antibody platform for HBV and Hepatitis Delta.
2. Gilead Sciences: The industry leader in antiviral therapies, currently testing various combination approaches for HBV.
3. Alnylam Pharmaceuticals: While a partner in some LNP contexts, Alnylam is a benchmark for RNAi technology and commercial execution.
4. GSK plc: Developing bepirovirsen, a late-stage antisense oligonucleotide that directly competes with Arbutus’s RNAi approach.
5. Moderna, Inc.: Now a settlement partner, Moderna remains an industry benchmark for LNP application and mRNA delivery.

Strategic Outlook and Innovation

The strategic focus for 2026 is the advancement of "Combination Immunotherapy." Management is prioritizing the IM-PROVE II trial, which evaluates imdusiran in combination with other immunomodulators to maximize functional cure rates. With the recent influx of settlement capital, Arbutus has pivoted from a "resource-constrained" biotech to a well-capitalized developer capable of running multiple late-stage trials simultaneously. The 2026 roadmap includes the launch of a registrational trial for imdusiran, aiming to solidify its position as the cornerstone of future HBV treatment protocols.

Innovation at Arbutus is led by its dual-pronged attack on HBV: using RNAi to "silence" the virus while using its oral PD-L1 inhibitor (AB-101) to "reawaken" the patient’s immune system. This liver-targeted approach is designed to avoid the systemic toxicity issues associated with traditional intravenous checkpoint inhibitors. Additionally, Arbutus continues to refine its LNP platform, exploring its utility in beyond-vaccine applications like gene editing and oncology. By integrating real-time viral kinetic modeling with its clinical data, Arbutus aims to personalize treatment durations, potentially offering patients a definitive end-date for therapy—a "holy grail" in chronic disease management.

Want more examples? ABT Covered Calls | ABX Covered Calls